Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Tapinarof
Drug ID BADD_D02597
Description Tapinarof is targeted as a topical cream treatment for psoriasis, a chronic autoimmune skin disease.
Indications and Usage Investigated for use/treatment in psoriasis and psoriatic disorders.
Marketing Status investigational
ATC Code Not Available
DrugBank ID DB06083
KEGG ID D11365
MeSH ID C571829
PubChem ID 6439522
TTD Drug ID D03DMB
NDC Product Code 58175-0646; 81672-5051; 61187-101
UNII 84HW7D0V04
Synonyms tapinarof | 3,5-dihydroxy-4-isopropylstilbene | benvitimod | 3,5-DH4IS | GSK2894512 | 2-isopropyl-5-(2-phenylethenyl)benzene-1,3-diol | 5-(2-phenylethenyl)-2-isopropyl-1,3-benzenediol | WBI-1001
Chemical Information
Molecular Formula C17H18O2
CAS Registry Number 79338-84-4
SMILES CC(C)C1=C(C=C(C=C1O)C=CC2=CC=CC=C2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--
Acne23.02.01.001--
Application site erythema08.02.01.001; 12.07.01.001; 23.03.06.005--
Application site irritation08.02.01.003; 12.07.01.003--
Application site pain08.02.01.004; 12.07.01.004--
Application site pruritus08.02.01.005; 12.07.01.005; 23.03.12.004--
Application site rash08.02.01.016; 12.07.01.016; 23.03.13.008--
Dermatitis contact10.01.01.003; 12.03.01.040; 23.03.04.004--
Erythema23.03.06.001--
Eyelid oedema06.04.04.004; 10.01.05.001; 23.04.01.003--
Headache17.14.01.001-
Hypersensitivity10.01.03.003-
Influenza like illness08.01.03.010-
Milia23.02.03.011--
Pain of skin23.03.03.003-
Pruritus23.03.12.001-
Psoriasis10.02.01.036; 23.03.14.002--
Rash23.03.13.001--
Skin discomfort23.03.03.006--
Skin exfoliation23.03.07.003--
Skin irritation23.03.04.009--
Swelling08.01.03.015--
Swelling face08.01.03.100; 10.01.05.018; 23.04.01.018--
Urticaria10.01.06.001; 23.04.02.001-
Skin burning sensation17.02.06.009; 23.03.03.021--
Inflammation08.01.05.007; 10.02.01.089--
Application site exfoliation08.02.01.022; 12.07.01.022; 23.03.07.007--
Keratosis pilaris23.01.01.002--
The 1th Page    1    Total 1 Pages